Evofem bags $25M to back novel contraceptive methods

att woman with phone

Evofem, a biotechnology company focused on women’s reproductive health, has closed on a Series D round of preferred stock financing that will amount to $25 million from Woodford Investment Management.

The San Diego, CA based startup counts among its products Amphora and Nestorone/Ethinyl Estradiol Ring (NES/EE), which are both currently in development.

Amphora has completed a Phase III clinical trial as a contraceptive and Evofem has submitted an application to the FDA for Amphora as a non-hormonal vaginal gel to be used as a contraceptive. There is ongoing work to look into Amphora having microbicidal properties.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"We are pleased that Woodford Investment Management recognizes the potential of our contraceptive technology which offers a meaningful alternative to women who desire non-hormonal contraception," said Saundra Pelletier, Evofem CEO, in a statement.

She continued, "Empowering women with access to innovative contraceptive options is the core of our business. We understand that women have changing needs regarding their reproductive choices and we want to offer non-hormonal, woman-controlled solutions."

NES/EE has gone through clinical trials and has shown it can be successfully used as a long-acting method of contraception that can be fully controlled.

Evofem is also developing other reproductive health options for women which aim to be non-hormonal, woman-controlled, on-demand and rapidly-reversible.

- here's the press release

Related Articles:
Study finds injectable birth control causes significant weight gain and changes in body mass

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.